Takeda is among the top 14 largest and 14th fastest growing pharmaceutical companies in the United States. We have more than 18,000 employees in the U.S. dedicated to helping patients across several parts of our business. Our U.S. Hub in Massachusetts is the operational center for the U.S. commercial business unit, Global R&D, Global Oncology, Global Vaccines, and biologics manufacturing.
ALUNBRIG® (brigatinib) FOR FIRST-LINE USE IN ALK+ METASTATIC NSCLC
For more information: www.alunbrig.com/hcp
NINLARO (Ixazomib) is indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy. For more information: www.ninlarohcp.com
Contact Information
Stu Hein
Oncology Territory Manager – Lung
Cell: (949) 690-5031
Email: Stu.Hein@takeda.com
Anthony Parsons
Oncology Territory Manager, Multiple Myeloma Franchise
Cell: (773) 320-6276
Email: Anthony.Parsons@takeda.com
Michelle Gillard, MSN, RN, CPHON
Clinical Nurse Educator, Takeda Oncology, Multiple Myeloma and Leukemia
Cell: (480) 231-0764
Email: michelle.gillard@takeda.com
